Selective histone deacetylase inhibitors

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 247-270

  Pan, Huili ^a   Cao, Jiangying ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anti cancer agents; HDAC; Histone deacetylase inhibitors; Selectivity

Indexed keywords

5 (TRIFLUOROACETYL)THIOPHENE 2 CARBOXAMIDE DERIVATIVE; AZUMAMIDE E; CHLAMYDOCIN; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; MOCETINOSTAT; ROMIDEPSIN; SIRTUIN; TUBACIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BRAIN; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL NUCLEUS; COMPLEX FORMATION; CYTOPLASM; DRUG MECHANISM; DRUG STRUCTURE; ENCHONDRAL OSSIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART; INHIBITION KINETICS; OVARY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION;

EID: 84863408932     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800228814     Document Type: Review

References (42)

1. Butler, K. V.; Kozikowski, A. P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr. Pharmaceutl Des., 2008, 14 (6), 505-528.
2. Zhang, Y.; Fang, H.; Jiao, J.; Xu, W. The structure and function of histone deacetylases: the target for anti-cancer therapy. Curr. Medicinal Chemistry, 2008, 15 (27), 2840-2849.
3. Maulucci, N.; Chini, M. G.; Micco, S. D.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M. C.; Casapullo, A.; Riccio, R.; Bifulco, G.; Riccardis, F. D. Molecular insights into azumamide e histone deacetylases inhibitory activity. J. Am. Chem. Soc., 2007, 129 (10), 3007-3012.
4. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem., 2003, 46 (24), 5097-116.
5. Moradei, O. M.; Mallais, T. C.; Frechette, S.; Paquin, I.; Tessier, P. E.; Leit, S. M.; Fournel, M.; Bonfils, C.; Trachy-Bourget, M. C.; Liu, J.; Yan, T. P.; Lu, A. H.; Rahil, J.; Wang, J.; Lefebvre, S.; Li, Z.; Vaisburg, A. F.; Besterman, J. M. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J. Med. Chem., 2007, 50 (23), 5543-5546.
6. Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J. H.; Reilly, J. F.; Ricker, J. L.; Richon, V. M.; Frankel, S. R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 2007, 109 (1), 31-39.
7. Mai, A.; Massa, S.; Lavu, S.; Pezzi, R.; Simeoni, S.; Ragno, R.; Mariotti, F. R.; Chiani, F.; Camilloni, G.; Sinclair, D. A. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem., 2005, 48 (24), 7789-7795.
8. Methot, J. L.; Hamblett, C. L.; Mampreian, D. M.; Jung, J.; Harsch, A.; Szewczak, A. A.; Dahlberg, W. K.; Middleton, R. E.; Hughes, B.; Fleming, J. C.; Wang, H.; Kral, A. M.; Ozerova, N.; Cruz, J. C.; Haines, B.; Chenard, M.; Kenific, C. M.; Secrist, J. P.; Miller, T. A. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg. Med. Chem. Lett., 2008, 18 (23), 6104-6109.
9. Tang, Y. A.; Wen, W. L.; Chang, J. W.; Wei, T. T.; Tan, Y. H.; Salunke, S.; Chen, C. T.; Chen, C. S.; Wang, Y. C. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PloS one, 2010, 5 (9), e12417.
10. Jones, P.; Steinkuhler, C. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents. Curr. Pharmaceut. Des., 2008, 14 (6), 545-561.
11. De Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. The Biochem. J., 2003, 370 (Pt 3), 737-749.
12. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic. J. Med. Chem., 2008, 51 (6), 1505-1529.
13. Simboeck, E.; Di Croce, L., HDAC1, a novel marker for benign teratomas. EMBO J,2010, 29 (23), 3893-3895.
14. Schuler, S.; Fritsche, P.; Diersch, S.; Arlt, A.; Schmid, R. M.; Saur, D.; Schneider, G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol. Cancer, 2010, 9, 80.
15. Bradner, J. E.; Mak, R.; Tanguturi, S. K.; Mazitschek, R.; Haggarty, S. J.; Ross, K.; Chang, C. Y.; Bosco, J.; West, N.; Morse, E.; Lin, K.; Shen, J. P.; Kwiatkowski, N. P.; Gheldof, N.; Dekker, J.; DeAngelo, D. J.; Carr, S. A.; Schreiber, S. L.; Golub, T. R.; Ebert, B. L. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. National Academy of Sciences USA, 2010, 107 (28), 12617-12622.
16. Fischer, A.; Sananbenesi, F.; Mungenast, A.; Tsai, L. H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci., 2010, 31 (12), 605-617.
17. Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem., 2003, 46 (23), 4826-4829.
18. Smil, D. V.; Manku, S.; Chantigny, Y. A.; Leit, S.; Wahhab, A.; Yan, T. P.; Fournel, M.; Maroun, C.; Li, Z.; Lemieux, A. M.; Nicolescu, A.; Rahil, J.; Lefebvre, S.; Panetta, A.; Besterman, J. M.; Deziel, R. Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19 (3), 688-692.
19. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)- selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem., 2005, 48 (9), 3344-3353.
20. Itoh, Y.; Suzuki, T.; Kouketsu, A.; Suzuki, N.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Design, synthesis, structure-- selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors. J. Med. Chem., 2007, 50 (22), 5425-5438.
21. Namdar, M.; Perez, G.; Ngo, L.; Marks, P. A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc. National Academy Sci. USA, 2010, 107 (46), 20003-20008.
22. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N. Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate. J. Med. Chem., 2006, 49 (16), 4809-4812.
23. Gupta, P. K.; Reid, R. C.; Liu, L.; Lucke, A. J.; Broomfield, S. A.; Andrews, M. R.; Sweet, M. J.; Fairlie, D. P. Inhibitors selective for HDAC6 in enzymes and cells. Bioorg. Med. Chem. Lett.,2010, 20 (23), 7067-7070.
24. Noureen, N.; Rashid, H.; Kalsoom, S. Identification of typespecific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother. Pharmacol., 2010, 66 (4), 625-633.
25. Krennhrubec, K.; Marshall, B. L.; Hedglin, M.; Verdin, E.; Ulrich, S. M. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17 (10), 2874-2878.
26. Estiu, G.; West, N.; Mazitschek, R.; Greenberg, E.; Bradner, J. E.; Wiest, O. On the inhibition of histone deacetylase 8. Bioorg. Med. Chem., 2010, 18 (11), 4103-4110.
27. Neugebauer, R. C.; Uchiechowska, U.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem., 2008, 51 (5), 1203-1213.
28. Pagans, S.; Pedal, A.; North, B. J.; Kaehlcke, K.; Marshall, B. L.; Dorr, A.; Hetzer-Egger, C.; Henklein, P.; Frye, R.; McBurney, M. W.; Hruby, H.; Jung, M.; Verdin, E.; Ott, M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol., 2005, 3 (2), e41.
29. Tervo, A. J.; Kyrylenko, S.; Niskanen, P.; Salminen, A.; Leppanen, J.; Nyronen, T. H.; Jarvinen, T.; Poso, A. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J. Med. Chem., 2004, 47 (25), 6292-6298.
30. Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, W.; Jung, M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Medicinal Chem., 2006, 49 (25), 7307-7316.
31. Zhang, L.; Fang, H.; Xu, W. Strategies in developing promising histone deacetylase inhibitors. Med. Res. Rev., 2010, 30 (4), 585-602.
32. Bertrand, P. Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem., 2010, 45 (6), 2095-2116.
33. Yurek-George, A.; Cecil, A. R.; Mo, A. H.; Wen, S.; Rogers, H.; Habens, F.; Maeda, S.; Yoshida, M.; Packham, G.; Ganesan, A. The first biologically active synthetic analogues of FK228, the depsipeptide histone deacetylase inhibitor. J. Med. Chem., 2007, 50 (23), 5720-5726.
34. Perez-Balado, C.; Nebbioso, A.; Rodriguez-Grana, P.; Minichiello, A.; Miceli, M.; Altucci, L.; de Lera, A. R. Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J. Med. Chem., 2007, 50 (10), 2497-2505.
35. Oyelere, A. K.; Chen, P. C.; Guerrant, W.; Mwakwari, S. C.; Hood, R.; Zhang, Y.; Fan, Y. Non-peptide macrocyclic histone deacetylase inhibitors. J. Med. Chem., 2009, 52 (2), 456-468.
36. Zhou, N.; Moradei, O.; Raeppel, S.; Leit, S.; Frechette, S.; Gaudette, F.; Paquin, I.; Bernstein, N.; Bouchain, G.; Vaisburg, A.; Jin, Z.; Gillespie, J.; Wang, J.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M. C.; Kalita, A.; Lu, A.; Rahil, J.; MacLeod, A. R.; Li, Z.; Besterman, J. M.; Delorme, D. Discovery of N-(2-aminophenyl)- 4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor. J. Med. Chem., 2008, 51 (14), 4072-4075.
37. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51 (10), 2898-2906.
38. Jones, P.; Altamura, S.; De Francesco, R.; Paz, O. G.; Kinzel, O.; Mesiti, G.; Monteagudo, E.; Pescatore, G.; Rowley, M.; Verdirame, M.; Steinkuhler, C. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem., 2008, 51 (8), 2350-2353.
39. Muraglia, E.; Altamura, S.; Branca, D.; Cecchetti, O.; Ferrigno, F.; Orsale, M. V.; Palumbi, M. C.; Rowley, M.; Scarpelli, R.; Steinkuhler, C.; Jones, P. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18 (23), 6083-6087.
40. Chen, Y.; Lopez-Sanchez, M.; Savoy, D. N.; Billadeau, D. D.; Dow, G. S.; Kozikowski, A. P. A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem., 2008, 51 (12), 3437-3448.
41. Wahhab, A.; Smil, D.; Ajamian, A.; Allan, M.; Chantigny, Y.; Therrien, E.; Nguyen, N.; Manku, S.; Leit, S.; Rahil, J.; Petschner, A. J.; Lu, A. H.; Nicolescu, A.; Lefebvre, S.; Montcalm, S.; Fournel, M.; Yan, T. P.; Li, Z.; Besterman, J. M.; Deziel, R. Sulfamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2009, 19 (2), 336-340.
42. Varghese, S.; Senanayake, T.; Murray-Stewart, T.; Doering, K.; Fraser, A.; Casero, R. A., Jr.; Woster, P. M. Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. J. Med. Chem., 2008, 51 (8), 2447-2456.